AI Thought Leader Allows prescribers to ask questions that elicit real-time responses from digital human avatars
CARMEL, Ind. , October 7, 2022 /PRNewswire/ — ParaPRO, a specialty pharmaceutical company specializing in innovative treatments for human ectoparasites, today announced that it will unveil AI Thought Leader – a pioneering medical education platform that allows healthcare practitioners to engage “live” with leading clinical experts on public health topics – at the American Academy National Conference & Expo of Pediatrics (AAP) at Anaheim, California, October 7-112022. The introduction of AI Thought Leader marks the first use of user-driven, interactive artificial intelligence (AI)-based technology to advance scientific exchange.
According Bill Culpepper 3President of ParaPRO, “We have developed AI Thought Leader to bring attention to the first FDA-approved “complete cure” for scabies, which has long been one of the most common, albeit underrepresented, public health problems. Because many doctors don’t often see scabies in their practice, it is often misdiagnosed or mistreated. This new technology allows us to share the knowledge and clinical experiences held by the privileged few with practitioners around the world, regardless of the physical barriers to in-person interaction.”
AAP conference attendees will be among the first to experience the educational benefits of AI Thought Leader specific to the identification, diagnosis and treatment of scabies, and featuring three of the most respected experts on the condition of the disease:
- Christopher BelcherMD, FAAP, Director of Pediatric Infectious Diseases, Peyton Manning Children’s Hospital, St. Vincent/Ascension
- Anthony J. Mancini, MD, FAAP, FAAD, Division Chief and Fellowship Associate Director, Dermatology, Ann & Robert H. Lurie Children’s Hospital of Chicago; Professor of Pediatrics and Dermatology, Northwestern University Feinberg School of Medicine
- Theodore RosenMD, FAAD, Professor of Dermatology at Baylor College of Medicine; Chief of Dermatology at the Michael E. DeBakey Veterans Affairs Medical Center
Visit ParaPRO at booth #1811 to see AI Thought Leader in action :
- October 8, 2022; 12:30 p.m. to 2:00 p.m. PST
- October 10, 2022; 12:00 p.m. to 1:30 p.m. PST
“The use of AI-based interactive technology is the future of scientific exchange,” said Christopher Belcher, MD, FAAP, Director of Pediatric Infectious Diseases, Peyton Manning Children’s Hospital, St. Vincent/Ascension. “Enabling prescribers to become agents of their own learning will redefine research-based medical education for years to come.”
For an overview AI Thought Leader and learn more, visit www.ThoughtLeaderAI.org.
About AI Thought Leader
AI Thought Leader is a pioneering medical education platform to advance public health. This revolutionary solution, a collaboration between ParaPRO and the University of Southern California Institute for Creative Technologies (ICT), enables prescribers to ask questions that elicit real-time answers from three highly respected physicians in the form of digital human avatars, using AI-based natural language processing, revolutionary filming techniques and specialized display technologies. Now and in the future, practitioners, fellows, and residents can have conversational interactions with these thought leaders across the physical boundaries of time and space.
Scabies is one of the most common and underrepresented global public health problems. It affects people of all races and social classes and can spread rapidly in crowded conditions where there is frequent close bodily contact. There are approximately 850,000 to 1 million cases of scabies in the United States each year.1
Scabies is caused by infestation of the skin by the human mite Sarcoptes scabiei var. Hominis. The microscopic scabies mite burrows into the top layer of the skin where it lives and lays its eggs. The most common symptoms of scabies are intense itching and a pimple-like rash. The scabies mite is usually spread by direct and prolonged skin-to-skin contact with a person who has scabies.2
ParaPRO LLC., a specialty pharmaceutical company focused on innovative antiparasitic formulations that minimize disruption and economic burden for patients and families and provides support to the wider professional community with the most knowledge, tools and resources. that educate and inform. In 2021, the company launched the first product (New Drug Application) for scabies to be approved by the U.S. Food and Drug Administration (FDA) in over 30 years and the only targeted topical therapy that addresses new FDA criteria for a “cure”. 3.4 For more information, visit www.ParaPRO.com.
- IQVIA March 2019-March 2021.
- Centers for Control and Prevention of Disasters. Parasites. https://www.cdc.gov/parasites/scabies/. Accessed 9/26/22.
- US FDA (nd). Orange Book: Approved Pharmaceuticals with Therapeutic Equivalence Assessments. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. Accessed 9/26/22.
- Data on file, ParaPRO, LLC